Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years old or older at the time you started treatment with the drug combination called SVd
- You have given your signed agreement to take part in the study (where required)
- You have been diagnosed with active multiple myeloma (a type of blood cancer) according to recognised international guidelines
- Your multiple myeloma has come back after one to three previous rounds of treatment
- You have already started treatment with SVd (meaning you have received at least one dose) since it became officially approved for use in Italy
- You have previously been treated with a drug called lenalidomide and your cancer stopped responding to it
Who may not be able to join:
- You have previously been treated with a drug called selinexor (one of the medicines in the SVd combination) at any point before this trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Elena Zamagni, UOC di Ematologia Policlinico S.Orsola AOU di Bologna
Phone: 0670390528
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
SdV therapy effectiveness in terms of Progression Free Survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.